MT Newswires
Halozyme Therapeutics Insider Sold Shares Worth $1,141,925, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
5/10
- Home
- HALO
as of 12-05-2025 3:44pm EST
$63.51
+$0.56
+0.89%
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Chart Type:
Time Range:
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.4B | IPO Year: | N/A |
| Target Price: | $73.33 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.74 | EPS Growth: | 56.68 |
| 52 Week Low/High: | $46.26 - $79.50 | Next Earning Date: | 11-03-2025 |
| Revenue: | $1,242,852,000 | Revenue Growth: | 31.19% |
| Revenue Growth (this year): | 32.47% | Revenue Growth (next year): | 24.31% |
AI-Powered HALO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 77.33%
77.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
Torley Helen
Sell
PRESIDENT AND CEO
HALO Dec 1, 2025
Avg Cost/Share
$69.98
Shares
16,569
Total Value
$1,141,924.75
Owned After
708,719
Connaughton Bernadette
Sell
Director
HALO Dec 1, 2025
Avg Cost/Share
$71.60
Shares
829
Total Value
$59,356.40
Owned After
42,123
SEC Form 4
Torley Helen
Sell
PRESIDENT AND CEO
HALO Nov 12, 2025
Avg Cost/Share
$70.99
Shares
20,000
Total Value
$1,410,990.47
Owned After
708,719
Torley Helen
Sell
PRESIDENT AND CEO
HALO Nov 11, 2025
Avg Cost/Share
$68.81
Shares
20,000
Total Value
$1,382,600.50
Owned After
708,719
Torley Helen
Sell
PRESIDENT AND CEO
HALO Nov 10, 2025
Avg Cost/Share
$69.01
Shares
20,000
Total Value
$1,374,338.60
Owned After
708,719
Connaughton Bernadette
Sell
Director
HALO Nov 10, 2025
Avg Cost/Share
$68.48
Shares
2,000
Total Value
$136,960.00
Owned After
42,123
SEC Form 4
Torley Helen
Sell
PRESIDENT AND CEO
HALO Oct 3, 2025
Avg Cost/Share
$70.14
Shares
20,000
Total Value
$1,380,638.14
Owned After
708,719
Torley Helen
Sell
PRESIDENT AND CEO
HALO Oct 2, 2025
Avg Cost/Share
$72.35
Shares
20,000
Total Value
$1,424,082.70
Owned After
708,719
Torley Helen
Sell
PRESIDENT AND CEO
HALO Oct 1, 2025
Avg Cost/Share
$75.40
Shares
20,000
Total Value
$1,507,024.28
Owned After
708,719
Connaughton Bernadette
Sell
Director
HALO Oct 1, 2025
Avg Cost/Share
$75.40
Shares
2,000
Total Value
$150,481.00
Owned After
42,123
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Torley Helen | HALO | PRESIDENT AND CEO | Dec 1, 2025 | Sell | $69.98 | 16,569 | $1,141,924.75 | 708,719 | |
| Connaughton Bernadette | HALO | Director | Dec 1, 2025 | Sell | $71.60 | 829 | $59,356.40 | 42,123 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Nov 12, 2025 | Sell | $70.99 | 20,000 | $1,410,990.47 | 708,719 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Nov 11, 2025 | Sell | $68.81 | 20,000 | $1,382,600.50 | 708,719 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Nov 10, 2025 | Sell | $69.01 | 20,000 | $1,374,338.60 | 708,719 | |
| Connaughton Bernadette | HALO | Director | Nov 10, 2025 | Sell | $68.48 | 2,000 | $136,960.00 | 42,123 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 3, 2025 | Sell | $70.14 | 20,000 | $1,380,638.14 | 708,719 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 2, 2025 | Sell | $72.35 | 20,000 | $1,424,082.70 | 708,719 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 1, 2025 | Sell | $75.40 | 20,000 | $1,507,024.28 | 708,719 | |
| Connaughton Bernadette | HALO | Director | Oct 1, 2025 | Sell | $75.40 | 2,000 | $150,481.00 | 42,123 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Zacks
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
📊
AI Sentiment
Positive
7/10
Insider Monkey
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) Following Appreciation
➖
AI Sentiment
Neutral
5/10
Compare HALO vs Leading Stocks
See how HALO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.